Table 1 Clinical characteristics of controls and asthmatic patients
From: Blood neutrophil activation markers in severe asthma: lack of inhibition by prednisolone therapy
| Â | Mild asthma | Moderate-to-severe asthma | Severe steroid-dependent asthma | Non-asthma controls |
|---|---|---|---|---|
n | 10 | 10 | 10 | 10 |
Gender M:F | 2:8 | 4:6 | 4:6 | 7:3 |
Mean age (years) | 35.8 | 47.7 | 50.9 | 36 |
[range] | 22–49 | 31–73 | 45–66 | 32–45 |
FEV1 (% predicted)1 | 95.8 ± 3.3 | 66.7 ± 5.0 | 51.4 ± 3.7 | 95 |
[range] | 75–112 | 38.5–85 | 30–70.7 | 92–98 |
Inhaled corticosteroid dose (BDP equivalent μg/day)1 | 0 | 1,900 ± 100 | 2,000 ± 0 | 0 |
Atopy* | 7 | 10 | 5 | 0 |
Exhaled NO (ppb) | 27.1 | 46.9 | 30.8 | ND |
[range] | 6.2–94 | 9.2–102 | 10.4–65.2 |  |